The company's development programs aim to address the underlying mitochondrial pathology and inflammation associated with Acute Kidney Disease, modify the intracellular and extracellular concentrations of electrolytes and ions in Chronic Kidney Disease and Gitelman’s Syndrome, and open the way for a broad range of disease-modifying therapies. Unicycive's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia, while UNI-494 is a new chemical entity in late preclinical development for the treatment of acute kidney injury. Founded in 2016 and headquartered in Los Altos, California, Unicycive Therapeutics is committed to improving the quality of life of kidney patients.